Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSimpson-Yap, Steve
dc.contributor.authorDe Brouwer, Edward
dc.contributor.authorKalincik, Tomas
dc.contributor.authorRijke, Nick
dc.contributor.authorHillert, Jan A.
dc.contributor.authorWalton, Clare
dc.contributor.authorZabalza de Torres, Ana
dc.contributor.authorArrambide García, Georgina
dc.date.accessioned2022-03-09T11:57:01Z
dc.date.available2022-03-09T11:57:01Z
dc.date.issued2021-11-09
dc.identifier.citationSimpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology. 2021 Nov 9;97(19):e1870–85.
dc.identifier.issn1526-632X
dc.identifier.urihttps://hdl.handle.net/11351/7128
dc.descriptionCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Esclerosi múltiple
dc.description.sponsorshipThe authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article. The operational costs linked to this study are funded by the Multiple Sclerosis International Federation (MSIF) and the Multiple Sclerosis Data Alliance (MSDA), acting under the umbrella of the European Charcot Foundation. The MSDA receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Canopy Growth Corp, Genzyme, Icometrix, Merck, Mylan, Novartis, QMENTA, Quanterix, and Roche. MSIF receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Genzyme, Med-Day, Merck, Mylan, Novartis, and Roche. This work was supported by the Flemish government under the Onderzoeksprogramma Artificiële Intelligentie Vlaanderen programme and the Research Foundation Fladers (FWO) for ELIXIR Belgium–Flanders (FWO) for ELIXIR Belgium. The central platform was provided by QMENTA, and the computational resources used in this work were provided by Amazon. The statistical analysis was carried out at CORe, The University of Melbourne, with support from the National Health and Medical Research Council (NHMRC; 1129189 and 1140766).
dc.language.isoeng
dc.publisherWolters Kluwer Health
dc.relation.ispartofseriesNeurology;97(19)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCOVID-19 (Malaltia) - Complicacions
dc.subjectEsclerosi múltiple - Tractament
dc.subject.meshCoronavirus Infections
dc.subject.mesh/complications
dc.subject.meshMultiple Sclerosis
dc.subject.mesh/drug therapy
dc.titleAssociations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1212/WNL.0000000000012753
dc.subject.decsinfecciones por Coronavirus
dc.subject.decs/complicaciones
dc.subject.decsesclerosis múltiple
dc.subject.decs/farmacoterapia
dc.relation.publishversionhttps://doi.org/10.1212/WNL.0000000000012753
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Simpson-Yap S] Department of Medicine, and Neuroepidemiology Unit, Melbourne School of Population & Global Health, University of Melbourne, Parkville, Australia. Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia [De Brouwer E] University of Tasmania, Hobart, Australia. ESAT-STADIUS, KU Leuven, Belgium. [Kalincik T] Department of Neurology, Melbourne MS Centre, Royal Melbourne Hospital, Parkville, Australia. [Rijke N, Walton C] MS International Federation, London, UK. [Hillert JA] Department of Clinical Neuroscience, Swedish MS Registry, Stockholm, Sweden. [Zabalza A, Arrambide G] Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid34610987
dc.identifier.wos000713678100016
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple